» Articles » PMID: 24867993

Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin Against Biofilm-forming Enterococcus Faecalis or E. Faecium in an in Vitro Pharmacodynamic Model Using Simulated Endocardial Vegetations and an in Vivo Survival Assay...

Overview
Specialty Pharmacology
Date 2014 May 29
PMID 24867993
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Enterococci are the third most frequent cause of infective endocarditis. A high-inoculum stationary-phase in vitro pharmacodynamic model with simulated endocardial vegetations was used to simulate the human pharmacokinetics of daptomycin at 6 or 10 mg/kg of body weight/day or linezolid at 600 mg every 12 h (q12h), alone or in combination with gentamicin at 1.3 mg/kg q12h or rifampin at 300 mg q8h or 900 mg q24h. Biofilm-forming, vancomycin-susceptible Enterococcus faecalis and vancomycin-resistant Enterococcus faecium (vancomycin-resistant enterococcus [VRE]) strains were tested. At 24, 48, and 72 h, all daptomycin-containing regimens demonstrated significantly more activity (decline in CFU/g) than any linezolid-containing regimen against biofilm-forming E. faecalis. The addition of gentamicin to daptomycin (at 6 or 10 mg/kg) in the first 24 h significantly improved bactericidal activity. In contrast, the addition of rifampin delayed the bactericidal activity of daptomycin against E. faecalis, and the addition of rifampin antagonized the activities of all regimens against VRE at 24 h. Also, against VRE, the addition of gentamicin to linezolid at 72 h improved activity and was bactericidal. Rifampin significantly antagonized the activity of linezolid against VRE at 72 h. In in vivo Galleria mellonella survival assays, linezolid and daptomycin improved survival. Daptomycin at 10 mg/kg improved survival significantly over that with linezolid against E. faecalis. The addition of gentamicin improved the efficacy of daptomycin against E. faecalis and those of linezolid and daptomycin against VRE. We conclude that in enterococcal infection models, daptomycin has more activity than linezolid alone. Against biofilm-forming E. faecalis, the addition of gentamicin in the first 24 h causes the most rapid decline in CFU/g. Of interest, the addition of rifampin decreased the activity of daptomycin against both E. faecalis and VRE.

Citing Articles

Evolutionary trajectories of β-lactam resistance in strains.

Ugalde Silva P, Desbonnet C, Rice L, Garcia-Solache M mBio. 2024; 15(12):e0289724.

PMID: 39540731 PMC: 11633384. DOI: 10.1128/mbio.02897-24.


From Polymeric Nanoformulations to Polyphenols-Strategies for Enhancing the Efficacy and Drug Delivery of Gentamicin.

Barzdina A, Plotniece A, Sobolev A, Pajuste K, Bandere D, Brangule A Antibiotics (Basel). 2024; 13(4).

PMID: 38666981 PMC: 11047640. DOI: 10.3390/antibiotics13040305.


Daptomycin-Impregnated PMMA Cement against Vancomycin-Resistant Germs: Dosage, Handling, Elution, Mechanical Stability, and Effectiveness.

Humez M, Domann E, Thormann K, Folsch C, Strathausen R, Vogt S Antibiotics (Basel). 2023; 12(11).

PMID: 37998769 PMC: 10668807. DOI: 10.3390/antibiotics12111567.


Synergistic properties of linezolid against Enterococcus spp. isolates: a systematic review from in vitro studies.

Antonello R, Riccardi N, Saderi L, Sotgiu G Eur J Clin Microbiol Infect Dis. 2023; 43(1):17-31.

PMID: 37975976 DOI: 10.1007/s10096-023-04704-8.


Eradication of Staphylococcus epidermidis within Biofilms: Comparison of Systemic versus Supratherapeutic Concentrations of Antibiotics.

Daffinee K, Piehl E, Bleick C, LaPlante K Antimicrob Agents Chemother. 2023; 67(6):e0010823.

PMID: 37154699 PMC: 10269123. DOI: 10.1128/aac.00108-23.


References
1.
Linden P . Treatment options for vancomycin-resistant enterococcal infections. Drugs. 2002; 62(3):425-41. DOI: 10.2165/00003495-200262030-00002. View

2.
LaPlante K, Woodmansee S . Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother. 2009; 53(9):3880-6. PMC: 2737833. DOI: 10.1128/AAC.00134-09. View

3.
Green S, Maddox J, Huttenbach E . Linezolid and reversible myelosuppression. JAMA. 2001; 285(10):1291. DOI: 10.1001/jama.285.10.1291. View

4.
Grohs P, Kitzis M, Gutmann L . In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother. 2002; 47(1):418-20. PMC: 148978. DOI: 10.1128/AAC.47.1.418-420.2003. View

5.
Shukla B, Gauthier T, Correa R, Smith L, Abbo L . Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review. Int J Clin Pharm. 2013; 35(5):697-703. DOI: 10.1007/s11096-013-9825-5. View